Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 30 11 2020
revised: 04 03 2021
accepted: 15 03 2021
pubmed: 27 3 2021
medline: 3 9 2021
entrez: 26 3 2021
Statut: ppublish

Résumé

To describe the characteristics, evolution and risk factors for long-term persistence of olfactory and gustatory dysfunctions (OGD) in COVID-19 outpatients. We conducted a prospective study in SARS-CoV-2 infected outpatients with OGD. Weekly phone interviews were set up starting from COVID-19 onset symptoms and over the course of 60 days, using standardized questionnaires that included a detailed description of general symptoms and OGD. The primary outcome was the proportion of patients with complete recovery of OGD at D30. Rate and time to recovery of OGD, as well as risk factors for late recovery (>30 days), were evaluated using Cox regression models. Ninety-eight outpatients were included. The median time to onset of OGD after first COVID-19 symptoms was 2 days (IQR 0-4). The 30-day recovery rate from OGD was 67.5% (95% CI 57.1-75.4) and the estimated median time of OGD recovery was 20 days (95% CI 13-26). Risk factors for late recovery of OGD were a complete loss of smell or taste at diagnosis (HR=0.26, 95% CI 0.12-0.56, P=0.0005) and age over 40 years (HR=0.56, 95% CI 0.36-0.89, P=0.01). COVID-19 patients with complete loss of smell or taste and over age 40 are more likely to develop persistent OGD and should rapidly receive sensorial rehabilitation.

Identifiants

pubmed: 33766735
pii: S2666-9919(21)00066-X
doi: 10.1016/j.idnow.2021.03.004
pmc: PMC7983360
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-444

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Références

Med Mal Infect. 2020 Aug;50(5):436-439
pubmed: 32305563
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
J Virol. 2008 Aug;82(15):7264-75
pubmed: 18495771
Nat Commun. 2020 Sep 11;11(1):4541
pubmed: 32917884
Otolaryngol Head Neck Surg. 2020 Jul;163(1):3-11
pubmed: 32369429
Am J Rhinol Allergy. 2020 Sep;34(5):686-693
pubmed: 32527141
Acad Radiol. 2020 Aug;27(8):1191
pubmed: 32425479
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Laryngoscope. 2020 Nov;130(11):2680-2685
pubmed: 32794209
Front Neurosci. 2014 Jun 26;8:182
pubmed: 25018692
Neuroscientist. 2021 Dec;27(6):582-603
pubmed: 32914699
J Laryngol Otol. 2020 Aug;134(8):703-709
pubmed: 32782030
Lancet Infect Dis. 2020 Sep;20(9):1015-1016
pubmed: 32304629
Mayo Clin Proc. 2020 Aug;95(8):1621-1631
pubmed: 32753137
Int Forum Allergy Rhinol. 2020 Sep;10(9):1065-1086
pubmed: 32567798
Laryngoscope. 2009 Mar;119(3):496-9
pubmed: 19235739
Am J Rhinol Allergy. 2014 Sep-Oct;28(5):419-22
pubmed: 25198029
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
J Neurol. 2020 Aug;267(8):2179-2184
pubmed: 32458193
Eur J Neurol. 2020 Sep;27(9):1738-1741
pubmed: 32320508
Adv Otorhinolaryngol. 2006;63:125-132
pubmed: 16733337
Head Neck. 2020 Jul;42(7):1583-1590
pubmed: 32437033
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288

Auteurs

L Cousyn (L)

Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France. Electronic address: louis.cousyn@gmail.com.

B Sellem (B)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

R Palich (R)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

D Bendetowicz (D)

Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France.

R Agher (R)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

C Delorme (C)

Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

R Tubiana (R)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

M-A Valantin (MA)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

S Seang (S)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

L Schneider (L)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

A Fayçal (A)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

Y Dudoit (Y)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

B Abdi (B)

Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France; Department of Virology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

A Ndoadoumgue (A)

Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

L Assoumou (L)

Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

C Katlama (C)

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH